CRA provided expert reports and testimony in several cases involving improper diversion of diabetes test strips. CRA’s damages analyses quantified the difference in profits earned on legitimate sales of test strips in the US retail market as compared to profits earned on the diverted test strips (for example, those sold in international markets or those intended for other patient groups in the US).
Anticompetitive conduct and patents listed in the Orange Book
Branded pharmaceutical manufacturers are required by law to list all patents in the Orange Book that cover an approved drug product. However,...